Bristol-Myers Squibb announced plans to lay off 4,300 employees and close more than half of its manufacturing plants in a cost-saving, "right-sizing" move. Followed by Pfizer and Merck, it's the third big pharma company to take action against the looming generics competition. In the Pipeline's Derek Lowe thinks it's not a bad thing, as long as R&D is left alone to do what they do best -- discover new drug compounds.